NCI Considers ‘Decentralization’ Of Group C To Provide Wider Access, Local Flexibility
In Brief: Broder Invokes Cancer Act Provision To Inform Hammer, Bush Of Potential Damage Of 32% Cut
Lasagna Committee Report Advocates Faster Drug approval, Insurance Coverage For Investigational Drugs, Ancillary Costs
Don’t Blame FDA For All Problems, Broder Says
Outside Experts Might Lengthen NDA Approval, Peck Asserts
Freement Lists Steps For Dealing With Disadvantaged
Trending Stories
- On Day 2 as director of NYU Perlmutter, Anirban Maitra talks about the advantages of running a matrix cancer center
- Mail-out colorectal cancer screening programs extend, rather than replace, clinical care
- Letai: NCAB’s ad hoc working group plays major role in advising NCI on extramural research
The group replaced the NCI Board of Scientific Advisors - Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched - Supportive cancer care is the smart investment our leaders in Washington can’t afford to ignore
- After a brief government shutdown, FY26 funding bill is signed into law
NIH gets $415M raise, NCI gets $128M more, CDMRP funding largely restored









